Quintessence Int 47 (2016), No. 7 (22.06.2016)
Page 571-580, doi:10.3290/j.qi.a36095, PubMed:27175451
Objective: To assess and compare the clinical and radiographic success
rates of biodentine and formocresol for pulpotomy in human primary
Method and Materials: A randomized, split-mouth,
double-blind, controlled clinical trial was carried out in 37 healthy 4-
to 8-year-old children with 56 pairs (112 teeth) of contralateral
primary molars indicated for pulpotomy. Matched teeth in each pair were
randomized to undergo either biodentine (n = 56 teeth) or formocresol (n
= 56 teeth) pulpotomy. In both groups, the teeth were restored with
stainless steel crowns. The teeth were evaluated clinically and
radiographically at 3 and 6 months by two blinded, standardized, and
calibrated examiners. The data were analyzed using chi-square and
McNemar tests with a P value of < .05 considered significant.
At both the 3- and 6-month follow-ups, all the 37 children with 112
treated teeth were evaluated. Clinical and radiographic success was
similar for biodentine (100%) and formocresol (100%), without any
statistically significant difference (P = 1). Pulp canal obliteration
was radiographically observed in 10/56 (17.9%) and 7/56 (12.5%) cases in
the biodentine and formocresol groups, respectively.
Both pulpotomy techniques showed favorable clinical and radiographic
outcomes at 3 and 6 months posttreatment without any significant
difference. Hence, biodentine has the potential to become a substitute
for formocresol in primary molar pulpotomies.